Female Mice Showed Slower THC Tolerance in a Formalin Pain Test
A formalin-test experiment found slower THC tolerance in female than male mice. That direction differs from findings in some other pain models, illustrating why there is no single sex-based cannabis-tolerance timetable.
Inflammatory behavior was the outcome
Investigators assessed formalin-evoked nociceptive behaviors in wild-type mice and animals carrying a desensitization-resistant CB1 receptor mutation. THC and CP55,940 were examined acutely and during repeated treatment. These were experimental pain behaviors, not reports from patients.
Sensitivity and tolerance again separated
Females were less sensitive to the acute antinociceptive effects of the tested cannabinoids, yet showed delayed THC tolerance relative to males. The receptor mutation also delayed THC tolerance in both sexes. A weaker initial response therefore did not mean more rapid adaptation in this assay.
The other agonist was not identical
CP55,940 showed a different pattern, including increasing sensitivity over time in female groups in selected comparisons. Results for one agonist should not be silently assigned to THC or interpreted as evidence that every endpoint followed the same trajectory.
Compare models before generalizing
The formalin assay differs from acute thermal testing and chemotherapy-evoked neuropathy. The paper does not show that women always develop THC tolerance more slowly, nor does another animal model prove the opposite universal rule. Sex, genotype, dose, test and disease context must remain attached to the finding. The value is a specific comparison that challenges overgeneralization, not a clinical prediction tool.
Related analysis: the different receptor-mutation finding in chemotherapy-related neuropathy.
Primary research
LaFleur RA; Wilson RP; Morgan DJ; Henderson-Redmond AN. Sex differences in antinociceptive response to Δ-9-tetrahydrocannabinol and CP 55,940 in the mouse formalin test. Neuroreport (2018). DOI: 10.1097/WNR.0000000000000993.
